Brief: Novel Human Genetics Evidence Confirms Estimates Of Genetic Prevalence, Underdiagnosis, And Potentially Greater Symptom Burden Of Gain-Of-Function CASR Variants Associated With ADH1
23/07/2025 12:44
July 23 (Reuters) - BridgeBio Pharma Inc BBIO.O: NOVEL HUMAN GENETICS EVIDENCE CONFIRMS ESTIMATES OF GENETIC PREVALENCE, UNDERDIAGNOSIS, AND POTENTIALLY GREATER SYMPTOM BURDEN OF GAIN-OF-FUNCTION CASR VARIANTS ASSOCIATED WITH ADH1 Source text: ID:nGNX1Kn4tx Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels